Syngene International (Large Cap - Potential Multibagger) Share Target 2025, 2026 To 2035
|
Syngene International Limited |
|||
|
Price: ₹713.75 (-0.12%) | ||
| 52 Week Low: ₹607.65 52 Week High: ₹960.60 |
|||
| Market Capital: 27,618.97 Crore (Largecap) | |||
| Healthcare -> Biotechnology | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Syngene International Share Price Target For 2025
- 1.1.1: Syngene International Share Price Target Table For 2025
- 1.1.2: Short-Term Technical Outlook
- 1.2: Syngene International Share Price Target For 2026
- 1.2.1: Syngene International Share Price Target Table For 2026
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Syngene International Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
- 3: Syngene International Brief Company Overview
- 4: Syngene International Financial Performance
- 4.0.1: Is Syngene International A Good Buy For Long Term?
Syngene International, a Large Cap company in the Biotechnology Industry has delivered 138.5% returns in 5-year with 14.6% profit margin, making it a potential Multibagger.
To predict the Syngene International's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Syngene International Share Price Target For 2025
The line chart displays the monthly closing prices of Syngene International with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Syngene International shares in 2025, see the table below.
Syngene International Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 788.75 (+10.5%) | Technical Indicator: MA250 |
| 2025 Target 2 | 780.0 (+9.27%) | Price Action: 26 Jul 2024 Low |
| 2025 Target 1 | 767.2 (+7.48%) | Price Action: 31 Jan 2025 High |
| Current Price | 713.75 | Syngene International's share price as of 21 Feb 2025 |
| Stop Loss 1 | 689.54 (-3.4%) | Price Action: 23 Jan 2024 High |
| Stop Loss 2 | 682.5 (-4.38%) | Price Action: 07 Mar 2024 Low |
| Stop Loss 3 | 675.6 (-5.35%) | Price Action: 21 Dec 2023 Low |
Short-Term Technical Outlook
Current Technical Position: Syngene International is displaying bearish momentum trading below key moving averages.
Key Technical Level: The 25-day moving average at ₹748.57 serves as the nearest technical reference point.
Historical Returns: 3-month: -24.13% | 6-month: -17.84% | 1-year: +1.27%
Syngene International Share Price Target For 2026
The line chart displays the monthly closing prices of Syngene International with a black line. The green line shows three potential target prices for 2026, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Syngene International shares in 2026, see the table below.
Syngene International Share Price Target Table For 2026
| Level | Value | Analysis |
|---|---|---|
| 2026 Target 3 | 948.8 (+32.93%) | Price Action: 03 Dec 2024 High |
| 2026 Target 2 | 938.0 (+31.41%) | Price Action: 10 Sep 2024 High |
| 2026 Target 1 | 928.5 (+30.08%) | Price Action: 13 Sep 2024 High |
| Current Price | 713.75 | Syngene International's share price as of 21 Feb 2025 |
| Stop Loss 1 | 660.89 (-7.41%) | Price Action: 19 Mar 2024 Low |
| Stop Loss 2 | 648.96 (-9.08%) | Price Action: 09 May 2024 Low |
| Stop Loss 3 | 642.21 (-10.02%) | Price Action: Dec 2020 High |
Long-Term Technical Outlook
52-Week Range Analysis: Syngene International is currently trading at 30.1% of its 52-week range (₹607.65 - ₹960.6).
Long-Term Trend Analysis: The stock is in a bearish long-term trend, trading below key long-term moving averages.
Long-Term Performance: 1-year: +1.27% | 3-year: +32.22% | 5-year: +138.47%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Syngene International Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹713.75 | ||
| 2025 | ₹994.46 | +39.32% | ₹1,009.38 |
| 2026 | ₹1,227.74 | +23.45% | ₹1,246.16 |
| 2027 | ₹1,679.54 | +36.79% | ₹1,704.73 |
| 2028 | ₹2,334.28 | +38.98% | ₹2,369.29 |
| 2029 | ₹2,700.47 | +15.68% | ₹2,740.98 |
| 2030 | ₹3,000.00 | +11.09% | ₹3,045.00 |
| 2031 | ₹3,741.49 | +24.71% | ₹3,797.61 |
| 2032 | ₹4,501.74 | +20.31% | ₹4,569.27 |
| 2033 | ₹5,087.83 | +13.01% | ₹5,164.15 |
| 2034 | ₹6,127.24 | +20.42% | ₹6,219.15 |
| 2035 | ₹7,040.51 | +14.9% | ₹7,146.12 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Syngene International Brief Company Overview
Syngene International Limited: A Leading Contract Research and Manufacturing Company Established in 1993, Syngene International Limited is a premier provider of drug discovery and development services. Product Range: Discovery Chemistry, Discovery Biology,...
Chemical Development Services: Lead Generation, Preclinical Development, Clinical Trial Management Market Presence: India, Japan, Europe, the United States, and internationally Reputation: Partnerships with industry giants like Bristol-Myers Squibb, Baxter Inc., and Amgen Inc. Commitment: Providing innovative solutions to clients across various sectorsSyngene International Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 27,618.97 Crore | Market valuation of Syngene International's shares. |
| Revenue (TTM) | 3,488.6 Crore | Total revenue generated by Syngene International over the past twelve months. |
| Net Income (TTM) | +510 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +23.53% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +14.61% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
-7.8% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
+5.5% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
13.04 | Company's total debt divided by total shareholder equity. |
| Total Debt | 555.2 Crore | Sum of Syngene International's current & long-term financial obligations. |
| Total Cash | 1,076.69 Crore | Total amount of liquid funds available to Syngene International. |
| Beta | 0.51 | Beta is less than 1 indicating that the Syngene International's price is less volatile than the market. |
Is Syngene International A Good Buy For Long Term?
Syngene International's financial performance for the last 12 months indicates a moderate revenue decline but a promising profit margin. While the company's earnings growth has been positive, it has been minimal compared to the previous year. Its financial position, with a low debt-to-equity ratio and ample cash reserves, is encouraging. However, recent returns show a mixed picture, with positive growth over the past three and five years but negative returns over shorter periods. Overall, Syngene International presents a relatively stable investment option with modest growth potential for long-term investors.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
